IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...

(RTTNews) - Edwards Lifesciences Corp. (EW) on Tuesday said its SAPIEN M3 mitral valve replacement system received U.S. Food and Drug Administration (FDA) approval for the treatment of mitral ...

Edwards Lifesciences Corp. today announced that it received CE Mark approval, the European equivalent of the Food and Drug Administration, for its Sapien M3 mitral replacement system. The device ...

One-year outcomes in the ENCIRCLE trial’s main cohort (299 patients unsuitable for other treatment options) achieved low rates for death and low heart failure hospitalization for patients treated with ...

The FDA has approved Edwards Lifesciences Corp.’s Sapien M3 transcatheter mitral valve replacement system. The U.S. approval, announced last week, comes eight months after the device received CE Mark ...

Please provide your email address to receive an email when new articles are posted on . A transseptal mitral valve replacement system was approved for patients unsuitable for surgery or transcatheter ...

Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as the world’s first transfemoral transcatheter mitral valve replacement ...

EVOQUE tricuspid valve registry demonstrates more favorable outcomes than pivotal trial SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced data demonstrating successful patient ...